{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:16:54Z","timestamp":1761513414809},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arab Journal of Gastroenterology"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.ajg.2014.01.003","type":"journal-article","created":{"date-parts":[[2014,2,5]],"date-time":"2014-02-05T00:45:59Z","timestamp":1391561159000},"page":"1-5","source":"Crossref","is-referenced-by-count":3,"title":["Entecavir 1mg versus combined lamivudine\/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study"],"prefix":"10.1016","volume":"15","author":[{"given":"Sahar","family":"Maklad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wahid","family":"Doss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameh Seif","family":"El Din","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamal","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alaa Abou","family":"Zeid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ajg.2014.01.003_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2004.07.003","article-title":"Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection","volume":"64","author":"Zoulim","year":"2004","journal-title":"Antivir Res"},{"issue":"12","key":"10.1016\/j.ajg.2014.01.003_b0010","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1046\/j.1537-2995.2002.00274.x","article-title":"Transmission transmitted HBV infection in an endemic area: the necessity of more scientific screening of HBV for carriers","volume":"42","author":"Wang","year":"2002","journal-title":"Transfusion"},{"key":"10.1016\/j.ajg.2014.01.003_b0015","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.ajg.2014.01.003_b0020","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.cgh.2008.08.021","article-title":"A treatment algorithm for the management of chronic hepatitis B in the United States 2008 update","volume":"6","author":"Keefee","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ajg.2014.01.003_b0025","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s10620-010-1255-9","article-title":"Long term effect of interferon therapy in patients with HBeAg positive chronic hepatitis B infection","volume":"56","author":"Senturk","year":"2011","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.ajg.2014.01.003_b0030","first-page":"1745","article-title":"Long term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis for up to 5years","volume":"131","author":"Hadziannis","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajg.2014.01.003_b0035","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1177\/135965350400900522","article-title":"Management of antiviral resistance in patients with chronic hepatitis B","volume":"9","author":"Locarnini","year":"2004","journal-title":"Antivir Ther"},{"key":"10.1016\/j.ajg.2014.01.003_b0040","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis hepatitis B and advanced liver disease","author":"Liaw","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajg.2014.01.003_b0045","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1053\/j.gastro.2003.09.033","article-title":"Long term safety of lamivudine treatment in patients with chronic hepatitis B","volume":"125","author":"Lok","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajg.2014.01.003_b0050","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A comparison of entecavir and lamivudine for HBeAg positive chronic hepatitis B","volume":"354","author":"Chang","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajg.2014.01.003_b0055","first-page":"136","article-title":"Entecavir maintains a high genetic barrier to HBV resistance through 6years in Naiive patients","author":"Tenny","year":"2009","journal-title":"Gastroenterology"},{"issue":"5 Suppl.","key":"10.1016\/j.ajg.2014.01.003_b0060","doi-asserted-by":"crossref","first-page":"S174","DOI":"10.1002\/hep.22900","article-title":"Antiviral resistance and hepatitis B therapy","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.ajg.2014.01.003_b0065","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.1002\/hep.22921","article-title":"Benefits and risks of combination therapy for hepatitis B","volume":"49","author":"Terrault","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.ajg.2014.01.003_b0070","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhep.2008.10.001","volume":"50","author":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B","year":"2009","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.ajg.2014.01.003_b0075","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/hep.22658","article-title":"Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir","volume":"49","author":"Leung","year":"2009","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.ajg.2014.01.003_b0080","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/hep.22323","article-title":"Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96weeks","volume":"48","author":"Sherman","year":"2008","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.ajg.2014.01.003_b0085","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/j.1440-1746.2008.05455.x","article-title":"Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients","volume":"23","author":"Suzuki","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.ajg.2014.01.003_b0090","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1128\/AAC.48.9.3498-3507.2004","article-title":"Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine","volume":"48","author":"Tenney","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.ajg.2014.01.003_b0095","first-page":"132","article-title":"Entecavir rescue therapy versus adefovir combination therapy in lamivudine-refractory patients with chronic hepatitis B","volume":"4","author":"Lee","year":"2010","journal-title":"Hepatol Int"},{"issue":"7","key":"10.1016\/j.ajg.2014.01.003_b0100","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1007\/s10620-010-1561-2","article-title":"Add-on adefovir is superior to a switch to entecavir as rescue therapy for lamuvidine-resistant chronic hepatitis B","volume":"56","author":"Chung","year":"2011","journal-title":"Dig Dis Sci"},{"issue":"8","key":"10.1016\/j.ajg.2014.01.003_b0105","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/j.1440-1746.2010.06381.x","article-title":"Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy","volume":"25","author":"Kim","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.ajg.2014.01.003_b0110","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1186\/1743-422X-8-393","article-title":"Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis","volume":"8","author":"Sheng","year":"2011","journal-title":"Virol J"},{"issue":"Suppl. 4","key":"10.1016\/j.ajg.2014.01.003_b0115","first-page":"514A","article-title":"Entecavir therapy for lamivudine resistant HBV cirrhotic patients waiting for olt: viral and biochemical outcomes at 1year","volume":"50","author":"Pellicelli","year":"2009","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.ajg.2014.01.003_b0120","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1053\/jhep.2001.29401","article-title":"Chronic hepatitis B","volume":"34","author":"Lok","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.ajg.2014.01.003_b0125","doi-asserted-by":"crossref","first-page":"S338","DOI":"10.1016\/S0168-8278(09)60932-6","article-title":"High risk of renal impairment during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B","volume":"50","author":"Vigano","year":"2009","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.ajg.2014.01.003_b0130","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/jmv.21898","article-title":"Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivdine-resistant chronic hepatitis B","volume":"82","author":"Ryu","year":"2010","journal-title":"J Med Virol"},{"issue":"5","key":"10.1016\/j.ajg.2014.01.003_b0135","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1053\/j.gastro.2007.08.079","article-title":"Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients","volume":"133","author":"Lampertico","year":"2007","journal-title":"Gastroenterology"}],"container-title":["Arab Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1687197914000070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1687197914000070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T07:17:30Z","timestamp":1688973450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1687197914000070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S1687197914000070"],"URL":"https:\/\/doi.org\/10.1016\/j.ajg.2014.01.003","relation":{},"ISSN":["1687-1979"],"issn-type":[{"value":"1687-1979","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}